Larvol Delta - ExpreS2ion-submits-Clinical-Trial-Application-CTA-to-conduct-Phase-I-study-of-ES2BC001-an-innovative-therapeutic-breast-cancer-vaccine

ES2B-C001 - ExpreS2ion

https://firstwordpharma.com/story/5882878

Aug 7, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next